ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhang, Suping ^a   Chen, Liguang ^a   Cui, Bing ^a   Chuang, Han Yu ^a   Yu, Jianqiang ^a   Wang Rodriguez, Jessica ^a   Tang, Li ^a   Chen, George ^a   Basak, Grzegorz W ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IEPSILON; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; UNCLASSIFIED DRUG; WNT5A PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; ROR1 PROTEIN, HUMAN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; TUMOR GROWTH; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHO CELL; CRICETULUS; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84863251015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031127     Document Type: Article

References (45)

1. Masiakowski P, Carroll RD, (1992) A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 267: 26181-26190.
2. Katoh M, Katoh M, (2005) Identification and characterization of rat Ror1 and Ror2 genes in silico. Int J Mol Med 15: 533-538.
3. Forrester WC, (2002) The Ror receptor tyrosine kinase family. Cell Mol Life Sci 59: 83-96.
4. Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, et al. (1999) Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 4: 41-56.
5. Wilson C, Goberdhan DC, Steller H, (1993) Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc Natl Acad Sci U S A 90: 7109-7113.
6. DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, et al. (2000) Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 24: 271-274.
7. Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, et al. (2000) Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 5: 71-78.
8. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, et al. (2001) Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 21: 8329-8335.
9. Afzal AR, Rajab A, Fenske CD, Oldridge M, Elanko N, et al. (2000) Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2. Nat Genet 25: 419-422.
10. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105: 3047-3052.
11. Oldridge M, Fortuna AM, Maringa M, Propping P, Mansour S, et al. (2000) Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B. Nat Genet 24: 275-278.
12. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, et al. (2007) Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 28: 318-326.
13. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, et al. (2008) Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 396-404.
14. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, et al. (2008) Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 123: 1190-1195.
15. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, et al. (2009) RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 106: 8695-8700.
16. MacKeigan JP, Murphy LO, Blenis J, (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7: 591-600.
17. Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, et al. (2010) Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol.
18. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM, (2011) Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 71: 3132-3141.
19. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
20. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
21. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
22. Chicha L, Tussiwand R, Traggiai E, Mazzucchelli L, Bronz L, et al. (2005) Human adaptive immune system Rag2-/-gamma(c)-/- mice. Ann N Y Acad Sci 1044: 236-243.
23. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273.
24. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
25. Mayr B, Montminy M, (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609.
26. Du K, Montminy M, (1998) CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379.
27. Kani S, Oishi I, Yamamoto H, Yoda A, Suzuki H, et al. (2004) The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase Iepsilon. J Biol Chem 279: 50102-50109.
28. Modak C, Bryant P, (2008) Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines. Biochem Biophys Res Commun 368: 801-807.
29. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32.
30. McGuire WL, (1975) Current status of estrogen receptors in human breast cancer. Cancer 36: 638-644.
31. Stoll BA, (1979) Endocrine therapy in cancer. Practitioner 222: 211-217.
32. Aggarwal S, Kim SW, Ryu SH, Chung WC, Koo JS, (2008) Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein. Cancer Res 68: 981-988.
33. Cheng JC, Kinjo K, Judelson DR, Chang J, Wu WS, et al. (2008) CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 111: 1182-1192.
34. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG, (2007) Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep 18: 953-958.
35. Linnerth NM, Greenaway JB, Petrik JJ, Moorehead RA, (2008) cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Int J Gynecol Cancer 18: 1248-1257.
36. Sakamoto KM, Frank DA, (2009) CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15: 2583-2587.
37. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM, (2010) Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 10: 384-391.
38. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459-4464.
39. Yang WS, Stockwell BR, (2008) Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol 9: R92.
40. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101: 3118-3123.
41. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, et al. (2006) Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A 103: 5454-5459.
42. Iozzo RV, Eichstetter I, Danielson KG, (1995) Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55: 3495-3499.
43. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL, (1995) Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1: 215-222.
44. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, et al. (2005) A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 115: 35-43.
45. Rice BW, Cable MD, Nelson MB, (2001) In vivo imaging of light-emitting probes. J Biomed Opt 6: 432-440.